Apimeds Pharmaceuticals US reported a net margin of -3,350.22% for the quarter ended Jun 2026. These financial ratios cover 10 quarters of results from Dec 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Ratios | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| EBT Margin | -3,350.22% | |||||||||
| EBIT Margin | -2,218.73% | |||||||||
| EBITDA Margin | -2,218.73% | |||||||||
| Operating Margin | -2,218.73% | |||||||||
| Net Margin | -3,350.22% | |||||||||
| Efficiency | ||||||||||
| Assets AverageAssets Avg. | 0.14M | 5.40M | 9.90M | 86.72M | 145.90M | |||||
| Invested CapitalInvested Cap. | 0.30M | -1.11M | -1.14M | 160.44M | 120.36M | |||||
| Leverage & Solvency | ||||||||||
| Interest Coverage RatioInterest Cover | -10.10 | -19.34 | -9.19 | -7.65 | -9.58 | -115.55 | -292.69 | -32.65 | -1.95 | |
| Debt Ratio | 0.63 | 19.15 | 2.40 | 0.04 | 0.11 | |||||
| Times Interest Earned | -10.10 | -19.34 | -9.19 | -7.65 | -9.58 | -115.55 | -292.69 | -32.65 | -1.95 | |
| Valuation | ||||||||||
| Price to EarningsP/E | -6.83 | -12.48 | -2.86 | -0.14 | ||||||
| Price to SalesP/S | 4.80 | |||||||||
| Price to BookP/B | 1.87 | 2.74 | 0.13 | 0.01 | ||||||
| Enterprise Value | 9.51M | 15.40M | -137.26M | -123.38M | ||||||
| EV to EBIT | -3.57 | -8.35 | 19.50 | 19.65 | ||||||
| EV to EBITDA | -3.57 | -8.35 | 19.50 | 19.65 | ||||||
| Market Capitalization | 18.25M | 22.39M | 20.62M | 1.36M | ||||||
| Price to FCFP/FCF | -5.43 | -12.80 | -5.37 | |||||||
| EV to FCF | -2.83 | -8.81 | 35.75 | |||||||
| EV to CFO | -2.83 | -8.92 | 35.95 | |||||||
| Return Ratios | ||||||||||
| Return on Sales [ROS]ROS | -2,218.73% | |||||||||
| Return on Capital Employed [ROCE]ROCE | 83.71% | -78.44% | -58.44% | -15.67% | -14.28% | |||||
| Return on Assets [ROA]ROA | -1,096.06% | -68.81% | -52.33% | -13.94% | -14.51% |